Biogen Inc. BIIB
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Revenue | $9.9B | +2% | FY ending Dec 31, 2025 |
|---|---|---|---|
| Gross profit | $11.6B | -6% | FY ending Dec 31, 2020 |
| Operating income | $2.8B | -38% | FY ending Dec 31, 2021 |
| Net income | $1.3B | -21% | FY ending Dec 31, 2025 |
| Earnings per share | $8.79 | -21% | FY ending Dec 31, 2025 |
| Research & development | $1.8B | -10% | FY ending Dec 31, 2025 |
| Cash from operations | $2.2B | -23% | FY ending Dec 31, 2025 |
| Capital spending | $153.8M | +0% | FY ending Dec 31, 2025 |
| Share buybacks | $0 | FY ending Dec 31, 2024 | |
| Cash | $3.0B | +27% | FY ending Dec 31, 2025 |
| Long-term debt | $6.3B | -0% | FY ending Dec 31, 2025 |
| Shareholders' equity | $18.3B | +9% | FY ending Dec 31, 2025 |
| Shares outstanding | 147M | +1% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 1 open-market buy ($585) and 4 sales ($905K) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lloyd MinorDirector | Sold | 593 | $200.96 | $119K | Aug 4, 2026 |
| Lloyd MinorDirector | Sold | 593 | $203.34 | $121K | Aug 3, 2026 |
| Nicole MurphyHead of Pharm Ops and Tech | Bought | 3 | $195.03 | $585 | Feb 12, 2026 |
| Priya SinghalHead of Development | Sold | 2,660 | $199.83 | $532K | Feb 9, 2026 |
| Priya SinghalHead of Development | Sold | 748 | $179.30 | $134K | Feb 2, 2026 |
Other insider moves (42): pay awards, option exercises, tax withholding, gifts
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sean GodboutChief Accounting Officer | Tax withholding | 8 | $219.88 | $1,759 | Oct 2, 2026 |
| Sean GodboutChief Accounting Officer | Option exercise | 27 | – | – | Oct 2, 2026 |
| William A HawkinsDirector | Award | 1,505 | – | – | Jun 9, 2026 |
| Stephen A SherwinDirector | Award | 1,505 | – | – | Jun 9, 2026 |
| Eric K RowinskyDirector | Award | 1,505 | – | – | Jun 9, 2026 |
| Jesus B MantasDirector | Award | 1,505 | – | – | Jun 9, 2026 |
| Susan LangerDirector | Award | 1,505 | – | – | Jun 9, 2026 |
| Monish D PatolawalaDirector | Award | 1,505 | – | – | Jun 9, 2026 |
| Menelas N PangalosDirector | Option exercise | 2,370 | – | – | Jun 9, 2026 |
| Menelas N PangalosDirector | Award | 1,505 | – | – | Jun 9, 2026 |
| Lloyd MinorDirector | Award | 1,505 | – | – | Jun 9, 2026 |
| Maria C FreireDirector | Award | 2,005 | – | – | Jun 9, 2026 |
| Adam KeeneyHead of Corporate Development | Tax withholding | 455 | $187.06 | $85K | May 1, 2026 |
| Adam KeeneyHead of Corporate Development | Option exercise | 939 | – | – | May 1, 2026 |
| Sean GodboutChief Accounting Officer | Tax withholding | 54 | $183.78 | $9,924 | Apr 1, 2026 |
| Sean GodboutChief Accounting Officer | Option exercise | 181 | – | – | Apr 1, 2026 |
| Christopher ViehbacherPresident and CEO, Director | Tax withholding2 fills | 10,980 | $201.18 avg | $2.2M | Feb 6, 2026 |
| Susan H AlexanderEVP Chief Legal Officer | Tax withholding3 fills | 3,504 | $201.18 avg | $705K | Feb 6, 2026 |
| Nicole MurphyHead of Pharm Ops and Tech | Tax withholding3 fills | 3,339 | $201.18 avg | $672K | Feb 6, 2026 |
| Ginger GregoryEVP, Human Resources | Tax withholding3 fills | 2,589 | $201.18 avg | $521K | Feb 6, 2026 |
| Priya SinghalHead of Development | Tax withholding2 fills | 2,468 | $201.18 avg | $497K | Feb 6, 2026 |
| Rachid IzzarHead of Global Product Strat. | Tax withholding3 fills | 2,038 | $201.18 avg | $410K | Feb 6, 2026 |
| Adam KeeneyHead of Corporate Development | Tax withholding2 fills | 1,583 | $201.18 avg | $318K | Feb 6, 2026 |
| Robin KramerChief Financial Officer | Tax withholding3 fills | 1,543 | $201.18 avg | $310K | Feb 6, 2026 |
| Jane GroganHead of Research | Tax withholding2 fills | 991 | $201.18 avg | $199K | Feb 6, 2026 |
| Sean GodboutChief Accounting Officer | Tax withholding3 fills | 359 | $201.18 avg | $72K | Feb 6, 2026 |
| Christopher ViehbacherPresident and CEO, Director | Option exercise2 fills | 24,461 | – | – | Feb 6, 2026 |
| Priya SinghalHead of Development | Option exercise2 fills | 6,900 | – | – | Feb 6, 2026 |
| Nicole MurphyHead of Pharm Ops and Tech | Option exercise3 fills | 8,725 | – | – | Feb 6, 2026 |
| Robin KramerChief Financial Officer | Option exercise3 fills | 5,003 | – | – | Feb 6, 2026 |
| Adam KeeneyHead of Corporate Development | Option exercise2 fills | 5,080 | – | – | Feb 6, 2026 |
| Rachid IzzarHead of Global Product Strat. | Option exercise3 fills | 6,889 | – | – | Feb 6, 2026 |
| Jane GroganHead of Research | Option exercise2 fills | 3,258 | – | – | Feb 6, 2026 |
| Ginger GregoryEVP, Human Resources | Option exercise3 fills | 7,183 | – | – | Feb 6, 2026 |
| Sean GodboutChief Accounting Officer | Option exercise3 fills | 1,079 | – | – | Feb 6, 2026 |
| Susan H AlexanderEVP Chief Legal Officer | Option exercise3 fills | 9,046 | – | – | Feb 6, 2026 |
| Priya SinghalHead of Development | Tax withholding | 582 | $179.89 | $105K | Jan 30, 2026 |
| Priya SinghalHead of Development | Option exercise | 1,829 | – | – | Jan 30, 2026 |
| Christopher ViehbacherPresident and CEO, Director | Tax withholding | 3,404 | $177.78 | $605K | Dec 1, 2025 |
| Christopher ViehbacherPresident and CEO, Director | Option exercise | 7,040 | – | – | Dec 1, 2025 |
| Jane GroganHead of Research | Tax withholding | 337 | $154.27 | $52K | Oct 31, 2025 |
| Jane GroganHead of Research | Option exercise | 695 | – | – | Oct 31, 2025 |
Trades by members of Congress
4 members reported 7 buys and 4 sales since Feb 25, 2025. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| Maria Elvira Salazar R | Sold some | $1,001–$15K | Sep 24, 2026 | Oct 7, 2026 | Self |
| Kevin Hern R | Sold | $1,001–$15K | Aug 18, 2026 | Sep 1, 2026 | Self |
| Maria Elvira Salazar R | Sold | $15K–$50K | Jun 2, 2026 | Jul 7, 2026 | Self |
| Gilbert Ray Cisneros, Jr. D | Bought | $1,001–$15K | Jun 5, 2026 | Jul 2, 2026 | Self |
| Maria Elvira Salazar R | Bought | $1,001–$15K | May 12, 2026 | Jun 8, 2026 | Self |
| Maria Elvira Salazar R | Bought | $1,001–$15K | May 11, 2026 | Jun 8, 2026 | Self |
| Maria Elvira Salazar R | Bought | $50K–$100K | May 11, 2026 | Jun 8, 2026 | Self |
| Gilbert Ray Cisneros, Jr. D | Bought | $1,001–$15K | Jan 30, 2026 | Feb 13, 2026 | Self |
| Robert P. Bresnahan, Jr. R | Bought | $1,001–$15K | May 15, 2025 | Jun 9, 2025 | Self |
| Robert P. Bresnahan, Jr. R | Sold | $1,001–$15K | Apr 8, 2025 | May 8, 2025 | Self |
| Robert P. Bresnahan, Jr. R | Bought | $1,001–$15K | Feb 25, 2025 | Mar 27, 2025 | Self |
Latest SEC filings
- Quarterly report 10-Q · Oct 28, 2026
- News filing: Quarterly results 8-K · Oct 28, 2026
- Insider plans to sell 144 · Aug 4, 2026
- Insider plans to sell 144 · Aug 3, 2026
- Quarterly report 10-Q · Jul 29, 2026
- News filing: Quarterly results 8-K · Jul 29, 2026
- News filing: Quarterly results 8-K · Jul 1, 2026
- News filing: Shareholder vote results 8-K · Jun 10, 2026
- News filing: Signed a major agreement, Bought or sold a business or assets, Took on new debt, Public announcement (Reg FD) 8-K · May 14, 2026
- Quarterly report 10-Q · Apr 29, 2026
- News filing: Quarterly results 8-K · Apr 29, 2026
- Shareholder meeting proxy DEF 14A · Apr 28, 2026
- News filing: Quarterly results 8-K · Apr 6, 2026
- News filing: Signed a major agreement, Other news 8-K · Mar 31, 2026
- News filing: Executive or board change 8-K · Mar 11, 2026
- News filing: Executive or board change, Other news 8-K · Feb 11, 2026
- Insider plans to sell 144 · Feb 9, 2026
- Annual report 10-K · Feb 6, 2026
- News filing: Quarterly results 8-K · Feb 6, 2026
- Insider plans to sell 144 · Feb 2, 2026
- News filing: Quarterly results 8-K · Jan 14, 2026
- Quarterly report 10-Q · Oct 30, 2025
- News filing: Quarterly results 8-K · Oct 30, 2025
- News filing: Quarterly results 8-K · Oct 14, 2025
- Insider plans to sell 144 · Sep 2, 2025
About Biogen Inc.
Business description
- Industry
- Biological Products, (No Diagnostic Substances)
- Sector
- Life Sciences
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Exchange
- Nasdaq
- Filer size
- Large accelerated filer
- Formerly
- BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
- SEC company number (CIK)
- 875045
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.